Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (previously presented) Eyedrops for promoting lacrimal secretion containing a natriuretic peptide as an active ingredient in an ophthalmic vehicle.

Claim 2. (previously presented) Eyedrops for treating a keratoconjunctival disorder containing a natriuretic peptide as an active ingredient in an ophthalmic vehicle.

Claim 3. (original) The eyedrops for treating the keratoconjunctival disorder as claimed in claim 2, wherein the keratoconjunctival disorder is at least one selected from dry eye, corneal erosion and corneal ulcer.

Claim 4. (previously presented) A method of treating a person having a keratoconjunctival disorder comprising

administering an effective amount of a natriuretic peptide to at least one eye of said person.

Claim 5. (previously presented) The method of claim 3 wherein said keratoconjunctival disorder is dry eye.

Claim 6. (previously presented) The method of claim 3 wherein said keratoconjunctival disorder is corneal erosion.

Claim 7. (previously presented) The method of claim 3 wherein said keratoconjunctival disorder is corneal ulcer.

Claim 8. (previously presented) The method of claim 4 wherein said natriuretic peptide is an atrial natriuretic peptide.

Claim 9. (previously presented) The method of claim 4 wherein said natriuretic peptide is a brain natriuretic peptide.

Claim 10. (previously presented) The method of claim 4 wherein said natriuretic peptide is a C-type natriuretic peptide.

Claim 11. (new) The method of claim 4 wherein the natriuretic peptide is administered as eyedrops in a concentration of 0.001 to 1% (W/V).

Claim 12. (new) The method of claim 4 wherein the natriuretic peptide is administered as eyedrops in a concentration of 0.005 to 0.5% (W/V).

Claim 13. (new) The method of claim 4 wherein the natriuretic peptide is administered as eyedrops in a concentration of 0.05 to 0.5% (W/V).